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Austen: Certain of the points raised during the 
discussion of specific papers did not, in my view, 
receive adequate attention; and thus I would like 
to return to them for consideration at this time. 
One issue relates to the in vitro assays for transfer 
factor, since a reproducible and sensitive assay of 
this material is absolutely essential to its ultimate 
definition. It would also be important to return to a 
consideration of the mechanism by which lym-
phocyte activation elicits fibrin deposition, espe-
cially in view of the fact that the deposition of 
fibrin appears to be different in a delayed-type 
hypersensitivity reaction than in immune complex 
lesions. We should also examine whether or not the 
basophil infiltration in a lymphocyte-dependent 
reaction can be looked upon as an effector mecha-
nism or a control event. The statement that the 
skin is a unique homing site for T -cells also merits 
further analysis. Finally, I would like to examine 
the evidence that the activation of the complement 
system in bullous diseases in fact contributes to 
the pathobiology observed in those states. Let me 
begin by asking Dr. Kirkpatrick and Dr. Spitler to 
review the transfer factor assay question. 
Kirkpatrick: There were several interesting re-
ports at the recent Transfer Factor Workshop. 
First, I would like to describe some of the animal 
models. There were reports from several labs of 
passive transfer of delayed hypersensitivity with 
dialyzable materials into cattle , dogs, monkeys, 
and mice. The responses were antigen specific. In 
mice, dogs, and monkeys, successful transfers 
occurred with human dialyzable transfer factor. In 
monkeys and cattle, homologous materials were 
used . 
It is peculiar that the guinea pig that has been 
the standard animal for studying delayed hypersen-
sitivity, appears to be a very poor animal for 
studying transfer factor. Dr. Welch of San Fran-
cisco has reported that passive transfer with trans-
fer factor in guinea pigs is successful if the animals 
are first primed with a skin test. Our experience 
with this model has been disappointing. We find 
that the skin test induces delayed hypersensitivity 
and that positive conversions occur with equal fre-
quency in both control and transfer factor-treated 
animals . 
The original model for in vitro assay of transfer 
factor involved material that was dialyzed into 
t issue culture medium. In the original report , there 
was a strong argument for specificity. More recent 
work indicates that this effect on enhancement of 
thymidine incorporation is nonspecific. That is, 
amplification occurs to antigens to which the 
transfer factor donor was unresponsive. And, as Dr. 
Spitler points out, the response is related to the 
intrinsic responsiveness of the responding cells . 
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The point is that the assays involving thymidine 
incorporation will probably not have wide applica-
tion in studying specificity of transfer factor in 
vitro . However, there are several labs that are 
using MIF and LIF production in vitro. The 
responses they obtain are antigen specific and my 
personal belief is that these experiments may be 
very informative in the future. 
Parenthetically, the experiments with column 
fractions in vitro have shown that either the 
enhancing effect on thymidine incorporation elutes 
off the columns over a wide area or, when peaks of 
activity are found, they are not always the same as 
the fractions that cause conversion of skin tests. 
There is too much adherence to the Sephadex gels 
to get clean, sharply defined fractions . 
Spitler: I take issue with Dr. Kirkpatrick 's 
comments. In my opinion, there is at the present 
time no assay of transfer factor other than the 
systemic transfer of reactivity in normal subjects 
which is sufficiently reliable to permit biochemical 
analysis of transfer factor . Various animal models 
have been reported for several years and, to date, 
there is no model that has been reproduced in more 
than one laboratory and shown to be a reliable 
assay for transfer factor. The in vitro test results 
from several laboratories clearly showed that the 
enhancement of antigen stimulation was related to 
the underlying reactivity of the recipient cells and 
had nothing to do with donor reactivity. Indeed, 
the effects of transfer factor in the lymphocyte 
stimulation test could be entirely reproduced by a 
similarly prepared extract of nonlymphoid tissue. 
Results in the leukocyte migration tests with 
measles antigen may well be related to the hemag-
glutinating activity present in the antigen prepara-
tion and , therefore, related to membrane changes 
rather than alteration of immune reactivity. Con-
siderable caution similarly must be used in the 
interpretation of results obtained by use of transfer 
of reactivity in patients with immunodeficiency 
and by use of local transfer of reactivity. 
Transfers in patients with immunodeficiency 
may not reflect transfer in normal subjects. We do 
not fully understand the basis of the immunodefi-
ciency in these patients and what is necessary to 
correct it. Transfer factor is a very crude prepara-
tion containing all the constituents of the cells with 
molecular weights under 20,000 (dialysable) which 
were present in the cell when it was lysed. It thus 
contains oligonucleotides, polypeptides , and many 
other substances. It is possible that one or more of 
these substances might correct the immunodefi-
ciency, but this might have nothing to do with 
systemic transfer of reactivity in normal subjects. 
Rocklin: I agree with Dr. Kirkpatrick that 
lymphocyte proliferation may not be the best in 
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vitro assay for transfer factor since there is no 
specificity in the response, and the degree to which 
the recipient cells are stimulated by transfer factor 
depends upon their baseline reactivity to the 
antigen. Some encouraging data were presented 
using either the macrophage or leukocyte migra-
tion inhibition assays to measure transfer factor 
activity with some specificity being demonstrated. 
I think the latter two assays deserve a critical look 
for their efficacy in this regard. Lastly, Levin et al 
[J Clin Invest 55:487, 1975] have demonstrated by 
using a lymphocyte-mediated cytoxicity system 
that cells from patients with osteogenic sarcoma 
become cytotoxic for osteogenic sarcoma cell lines 
after exposure to transfer factor. 
Schwartzman: I have no personal experience 
with transfer factor and know of no reports dealing 
with its use in domesticated animals. However, I 
would like to make note of our observation that 
domesticated animals are relatively poor in their 
ability to develop delayed hypersensitivity reac-
tions when compared to man or guinea pigs. We 
have never been able to induce delayed hypersensi-
tivity reactions in the cat; and in the dog, the only 
successful method has been through the injection 
of BCG. 
Rocklin: I would like to mention one possible 
mechanism by which a lymphocyte product might 
initiate the clotting sequence and account for the 
fibrin deposition in cellular immune reactions. 
Antigen-activated and mitogen-activated lympho-
cytes produce a procoagulant material [Rickles FR 
et al: J Clin Invest 52 : 1427, 1973 ] which corrects 
the clotting time of Hageman-deficient plasma . 
This material has been identified antigenic ally as 
being tissue factor. It, therefore , could activate the 
clotting system via the extrinsic pathway. Macro-
phages also elaborate this material in large 
amounts as do other tissue cells. 
Dvorak: I am not at all surprised that lympho-
cytes make a procoagulant. Lymphocytes are mar-
velous cells that make a seemingly limitless series 
of mediators. What remains to be established is 
whether lymphocytes are responsible or necessary 
for the deposits of fibrin occurring in delayed 
reaction in man and animals. It is possible to argue 
that extravasated fibrinogen should polymerize on 
contact with the collagen of basement membrane 
on the dermis. If this is correct, and fibrinogen 
injected into guinea pig skin does clot, then lym-
phocytes might not be necessary in the pathogen-
esis of fibrin deposition in delayed reactions. 
Indeed, what requires explanation is the paradoxi-
cal lack of fibrin deposits in vessel walls and the 
perivascular lymphoid cuff about vessels. Fibrin is 
deposited extensively in these areas in immune 
complex vasculitis and the fibrinogen concentra-
tion in this zone would be expected to be higher 
than in areas of the dermis further from vessels. 
Therefore, the molecules to look for may be an 
anticoagulant or a fibrinolysin. Mast cells may 
contain the former (heparin), and macrophages the 
latter (plasminogen activators). 
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Epstein: Basophil-rich cutaneous basophil hy-
persensitivity reactions in the guinea pig have very 
little fibrin deposition as compared with that 
occuring in classic delayed hypersensitivity. They 
also exhibit a much smaller increase in vascular 
permeability than true delayed reactions. The 
functional role played by mast cells and basophils 
in cell-mediated reactions, whether related to his-
tamine or other vasoactive mediator release or to 
release of a heparin-like material, remains to be 
elucidated. 
Warren: If the animals were pretreated with 
ellagic acid which activates Hageman factor and 
leads to consumptive depletion of Hageman factor-
dependent systems, the plastic bead granuloma 
was completely suppressed. When schistosome 
eggs were injected into ellagic acid-treated mice, 
there was also significant suppression of this 
delayed hypersensitivity mediated reaction. When 
plastic beads were injected into pigeons which are 
deficient in Hageman factor, no granulomas were 
seen . Schistosome eggs did, however, induce mod-
erate-sized granulomas and a sensitization phe-
nomenon was seen. 
Austen: Since ellagic acid activates the Hage-
man factor, its effects are not limited to the 
generation of bradykinin by cleavage of kininogen. 
It should be noted that there are three distinct 
Hageman factor substrates: plasma thromboplas-
tin anteceden t (PTA), prekallikrein, and plas-
minogen pro activator. Thus, conversion of Hage-
man factor to its active state elicits coagulation, 
fibrinolysis , and kinin generation . When ellagic 
acid pretreatment diminishes the size of the 
immunologically induced granuloma in animals 
with schistosomiasis, the effect could be attributed 
to anyone of these three Hageman factor-depend-
ent pathways being depleted. 
Weston: The cellular source of tissue coagula-
tion factor in delayed hypersensitivity reactions 
may indeed be the monocyte macrophage. When 
we compare purified human lymphocyte popula-
tions to monocyte populations activated by adher-
ence to glass, it is evident that tissue factor is 
produced by "activated" monocyte-macrophages 
[Rivers RPA, Hathaway WE, Weston WL, Br J 
Haematol 30:311, 1975]. 
Lazarus: It has been shown that endothelial 
cells have tissue factor . Perhaps the endothelial 
cell activation demonstrated by Drs. Mihm and 
Dvorak could be responsible for increased tissue 
factor levels, if such a phenomenon exists, in these 
diseases. 
Austen: Fibrin in cutaneous basophil hypersen-
sitivity is found largely between blood vessels and 
thus either is caused by cells present in these 
tissues, such as histiocytes, or is prevented from 
persisting in the blood vessels by virtue of some 
cell with profound fibrolytic potential. I wonder 
whether Dr. Dvorak could offer his assessment of 
this situation? 
Dvorak: Endothelial cell hypertrophic and 
other changes are much less well developed in 
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guinea-pig delayed reactions than in those occur-
ring in man as detected by simple microscopy. 
Metabolic studies (for example, thymidine incor-
poration) are in progress to determine whether 
endothelial cells in guinea-pig delayed reactions 
exhibit activation. 
Austen: Dr. Zucker-Franklin, would you return 
to the question of whether or not there are specific 
mechanisms for T -cells homing to skin? 
Zucker-Franklin: I think the question as to 
whether T -cells "home" . to the skin has not been 
answered and will be a very difficult one to answer. 
Since the number of T -cells in circulating blood ·is 
so much greater than the number of B-cells, any 
nonspecific lymphocyte infiltrate of the skin would 
be dominated by T -lymphocytes. In order to know 
whether B-cells are equally able to infiltrate the 
skin, one should look at patients with high levels of 
B-Iymphocytes, such as patients with cirrhosis or 
rheumatoid arthritis. For example, would we find 
B-Iymphocytes in biopsies of the rash in children 
with juvenile rheumatoid arthritis? Secondly, do 
all patients with T -celllymphoproliferative disease 
have skin involvement? The vast majority of 
patients with Hodgkin's disease, as well as children 
with T-cell lymphoblastic leukemia, have no skin 
involvement whatsoever . 
Edelson: The most exciting explanation of the 
observations which I presented is that a normal 
population of T -cells, perhaps helper T -cells, home 
in the skin but also rapidly recirculate through the 
body. The cutaneous T-cell leukemias, as neo-
plastic amplifications of this normal situation, 
would be expected to present as infiltrations of the 
skin by the abnormal T-cells. A number of reasons, 
mentioned at the end of my paper, emphasize a 
possible relationship between the epidermis and 
the thymus. 
Austen: I would like to ask Dr . Provost and Dr. 
Jordon ab011t the role of complement in pemphigus 
and pemphigoid. Is there any evidence that activa-
tion of the complement system contributes to the 
disease process? It is obvious that if immune 
complexes form and actually are present in the 
bullous fluid, there will be complement component 
abnormalities-providing that the immunoglobu-
lin is of the right class. Furthermore, since factor B 
and properdin are part of the amplification mecha-
nism initiated by the availability of the major 
cleavage fragment of C3, namely C3b, the deposi-
tion of these two principles does not distinugish 
amplification of classic pathway activation from 
involvement at the initiating level of the alterna-
tive route. 
Provost: Heavy depositions of immunoglobulin 
and complement are often found in normal skin of 
patients with systemic lupus erythematosus in the 
absence of history and histologic eviqence of 
inflammation. Dr. Gilliam has also observed simi-
lar findings. Heavy complement deposition is, at 
times, found in normal-appearing skin of bullous 
pemphigoid patients. We talk in terms of comple-
ment tissue deposition being equated with activa-
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tion. The above observations may indicate that 
this may not always be so. 
Jordon: I'm afraid that I must agree at the 
present time with Dr. Provost's comments as most 
of the complement studies done by us provide only 
circumstantial evidence for complement-mediated 
pathogenetic damage. I disagree, however, that 
significant complement deposition occurs in nor-
mal skin. In pemphigus, I have never detected 
complement in uninvolved skin; in bullous pem-
phigoid, only occasionally. 
Sams: Because of the studies which Dr. Jordon 
described at this meeting and the observation that 
polymorphonuclear leukocytes are frequently 
found within blisters of bullous pemphigoid, par-
ticularly along the edge of the basal lamina, it was 
proposed that some moiety within the basal lamina 
becomes antigenic [Arch Dermatol 102:485, 1970]. 
Serum antibodies are formed to this structural 
antigen, complement is fixed, chemotactic factors 
are released, and polymorphonuclear leukocytes 
infiltrate the area, releasing their lysosomal 
enzymes which cause dissolution of the anchoring 
fibrils. A cavity forms which fills with fluid, 
resulting in a clinical blister. A number of studies 
were designed to prove this hypothesis but none 
were successful. Last year, Beno Michel and his 
colleagues at Case Western Reserve described a 
critical experiment which, if proven to be correct, 
will have great significance in confirming the above 
hypothesis. They demonstrated that if one grew 
whole skin in organ culture and then added pem-
phigoid serum to it, nothing happened. However, if 
one added pemphigoid serum and polymorphonu-
clear leukocytes, a separation took place at the 
dermoepidermal junction, thus assigning a 
pathomechanistic role to serum and to cells. I 
understand that these studies are in press and we 
shall shortly have an opportunity to examine the 
data more closely. 
Provost: Passive transfer studies with high-titer 
pemphigus and pemphigoid sera have given incon-
sistent results in the production of blistering dis-
ease in animal models. I think these studies 
caution us about our eagerness to ascribe the 
pathogenesis of these diseases to complement acti-
vation. 
Katz: It is difficult to reconcile the very ~arliest 
ultrastructural changes with the ultrastructural 
localization of horseradish peroxidase-labeled 
anti-C3 in pemphigoid and herpes gestations. The 
location of C3 is very close but not in the exact 
location of early changes. Dr. Yaoita and I have 
proposed that perhaps the earliest changes may 
not be linked to C3 activation at all or that C3 may 
set off another enzymic destructive system. 
Austen: Dr. Claman, would you address yourself 
to the role of the mast cell and basophil in 
cell-mediated immunity. That is, do you feel that 
this is a regulatory or effector cell? 
Claman: With regard to mast cell involvement 
in contact sensitivity to DNFB, all I ·can speak 
about is the mouse. Here we see mast cell degranu-
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lation but only at 4 hr; at 24 hr, the mast cells have 
returned to normal. Dr. Dvorak and I discussed 
this and agree that it may mean an involvement of 
cytophilic antibody of either the IgG 1 or IgE class. 
With regard to basophilic infiltrations, one won-
ders whether these are primary or secondary. 
Although they first appear "early" in the delayed 
reaction, i.e., at 4 to 8 hr, this may, in fact, not be 
"early". Although the reaction peaks at 24 to 48 hr, 
presumably the events actually begin at time O. 
Therefore, I think the question of whether these are 
primary or secondary cells is unanswerable. 
Austen: In closing, I would indeed state that we 
have achieved our goal of bringing together the 
disciplines of dermatology and immunology to 
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create an effective initial analysis of the discipline 
of immunodermatology. The virtues of this analy-
sis are not limited only to a more detailed appreci-
ation of the mechanisms of dermatologic diseases 
but also are found in the recognition that skin 
disease may be the most useful circumstance in 
which to conduct investigations in the area broadly 
defined as "clinical immunology." The opportu-
nity to combine clinical observation with structural 
characterization of tissue alterations and chemical 
analysis of effector systems is perhaps unique, 
especially with regard to the opportunity to carry 
out time-dependent studies and to develop proper 
control materials and experience. 
